| Literature DB >> 33754721 |
Hiroki Kitagawa1, Masaki Kikuchi2, Shin Sato2, Hisami Watanabe2, Naoki Umezawa1, Maiko Kato1, Yosuke Hisamatsu1, Takashi Umehara2, Tsunehiko Higuchi1.
Abstract
Peptides are attractive drug candidates, but their utility is greatly limited by their inherent susceptibility to proteolytic degradation and their inability to pass through the cell membrane. Here, we employ a strategy of temporary cyclization to develop a cell-active lysine-specific demethylase 1 (LSD1/KDM1A) inhibitor peptide. We first identified a highly potent LSD1-inhibitory linear peptide, with the assistance of X-ray crystal structure data of inhibitor peptide-bound LSD1·CoREST. The peptide was converted to a redox-activatable cyclic peptide incorporating cell-penetrating peptide (CPP), expecting selective activation under intracellular reducing conditions. The cyclic peptide moiety exhibited enhanced stability to protease and was converted to the linear, unmodified LSD1 inhibitor peptide under reducing conditions. The cyclic peptide with CPP inhibited the proliferation of human acute myeloid leukemia cells (HL-60) in the low micromolar concentration range.Entities:
Year: 2021 PMID: 33754721 DOI: 10.1021/acs.jmedchem.0c01371
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446